RT Journal Article
SR Electronic
T1 Multiplexed and extraction-free amplification for simplified SARS-CoV-2 RT-PCR tests
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.21.20106195
DO 10.1101/2020.05.21.20106195
A1 Byrnes, Samantha A.
A1 Gallagher, Ryan
A1 Steadman, Amy
A1 Bennett, Crissa
A1 Rivera, Rafael
A1 Ortega, Corrie
A1 Motley, S. Timothy
A1 Jain, Paras
A1 Weigl, Bernhard H.
A1 Connelly, John T.
YR 2020
UL http://medrxiv.org/content/early/2020/05/26/2020.05.21.20106195.abstract
AB The rapid onset of the global COVID-19 pandemic has led to multiple challenges for accurately diagnosing the infection. One of the main bottlenecks for COVID-19 detection is reagent and material shortages for sample collection, preservation, and purification prior to testing. Currently, most authorized diagnostic tests require RNA extraction from patient samples and detection by reverse transcription polymerase chain reaction (RT-PCR). However, RNA purification is expensive, time consuming, and requires technical expertise to perform. Additionally, there have been reported shortages of the RNA purification kits needed for most tests. With these challenges in mind, we report on extraction-free amplification of SARS-CoV-2 RNA directly from patient samples. In addition, we have developed a multiplex RT-PCR using the CDC singleplex targets. This multiplex has a limit of detection of 2 copies/μL. We have demonstrated these improvements to the current diagnostic workflow, which reduce complexity and cost, minimize reagent usage, expedite time to results, and increase testing capacity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding was provided by the Bill and Melinda Gates Foundation Trust through The Global Good Fund I, LLC (www.globalgood.com) at Intellectual Ventures. The Global Good Fund I, LLC provided support in the form of salaries for SAB, RG, AS, CB, RR, CO, STM, PJ, BHW, and JTC, as well as financial support for the study, but did not have any additional role in study design, data collection and interpretation, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All clinical samples used in this study were discarded, de-identified samples and therefore did not require IRB approval. We've updated the manuscript to reflect this information.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is provided in the Supporting Information.